ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025
ImmunityBio's stock traded higher by 37% after dosing the first patient in its phase 1 QUILT 106 study for CD19+/CD20+ NHL, with data expected in 2025. The company's ANKTIVA therapy, combined with Keytruda or Opdivo, showed promising results in phase 2b for NSCLC, leading to upcoming phase 3 studies. The company has around $130.1 million in cash, bolstered by a $100 million infusion, enough to fund operations for at least the next 12 months.
ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock?
ImmunityBio (IBRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
EF Hutton has initiated coverage on ImmunityBio Inc. IBRX, a vertically integrated biotechnology company developing therapies and vaccines to bolster the natural immune system for cancers and infectious diseases.
ImmunityBio: Moving The Needle
ImmunityBio's ANKTIVA shows promising commercial and clinical progress, with expanded patient access and potential EU/UK regulatory filings, enhancing its global market penetration and revenue prospects. Recent positive clinical data for ANKTIVA in NSCLC and endometrial cancer trials highlight its potential beyond bladder cancer, boosting its long-term growth outlook. Despite significant advancements, risks include regulatory hurdles, commercialization challenges, high cash burn, and reliance on founder Dr. Patrick Soon-Shiong for funding.
ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt
Anktiva, ImmunityBio's lead molecule, shows promising results with a 71% CR rate and 100% survival at 24 months for BCG-unresponsive NMIBC. Despite Anktiva's potential, ImmunityBio faces financial challenges, relying heavily on loans from founder Dr. Soon-Shiong, leading to high indebtedness. The company has a market cap of $2.43bn but limited cash runway, raising concerns about its financial stability and lack of recent earnings calls.
ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'
ImmunityBio received FDA approval for ANKTIVA plus BCG for BCG-unresponsive bladder cancer in April. The drug has a unique mechanism of action. Immunity's early launch progress of Anktiva shows promising market access initiatives, but financial concerns remain due to high R&D costs. Analysts project peak revenues of ~$900m by 2028 for Anktiva, although at present, Immunity's pricing of the drug is a little hard to understand.
ImmunityBio (IBRX) Reports Q2 Loss, Lags Revenue Estimates
ImmunityBio (IBRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.28 per share a year ago.
ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why
ImmunityBio (IBRX) rises 17% in the past week as it announces insurance coverage as well as the treatment of the first patients with its newly approved bladder cancer immunotherapy, Anktiva.
ImmunityBio: Anktiva's Launch Demands A Reassessment
ImmunityBio's flagship product, Anktiva, has been launched in the market for the treatment of bladder cancer, with strong clinical data supporting its efficacy. The company is well-prepared for the launch, with a strong sales force, established distribution channels, and sufficient inventory. Analyst projections suggest significant growth for ImmunityBio, with the potential for Anktiva to become a blockbuster drug and drive the company's revenue in the coming years.
